Skip to content
Cover: glowing NK immune cells attacking an abnormal cell

KEYCELL-IM inj.: EHL Bio's multi-immune-cell cancer therapy

NK, T, dendritic and iNKT cells cultured separately, infused together

Quick answer

KEYCELL-IM inj. is EHL Bio's immune cell therapy: NK, T, dendritic and iNKT cells are separated from the patient's own blood, each activated and expanded with proprietary culture technology, cryopreserved, then expanded for infusion. Its selling point is that a single apheresis collection yields roughly 30 times more cells than a standard blood draw, enough for 6-12 doses.

Key facts

Product
KEYCELL-IM inj.
Cell types
NK, T, dendritic, iNKT
Collection
Single apheresis, ~30x more cells
Doses per collection
6-12 doses
NK cell status
Preclinical complete (lung cancer)

Innate and adaptive immunity in brief

Immunity has an innate arm (macrophages, NK cells, granulocytes) and an adaptive arm (B and T cells), with dendritic and gamma-delta T cells presenting antigen to bridge the two.

Why KEYCELL-IM combines several cell types

The concept is combination: dendritic cells present tumour antigen, T lymphocytes and NK cells attack abnormal cells, and iNKT cells boost overall immune activity — unlike older single-cell-type approaches.

Separate culture lines and dose control

The company says culturing each type separately keeps the dose composition consistent, unlike mixed culture where ratios drift. Its NK cell programme for lung cancer has completed preclinical study.

An adjunct, never a replacement for oncology care

Important context: this class of cell immunotherapy is adjunctive alongside standard treatment such as surgery, chemotherapy or radiotherapy — not a replacement — and belongs under oncologist supervision.

Frequently asked questions

  • Can cell immunotherapy replace chemotherapy?

    No. It should complement the oncologist's plan; abandoning standard therapy for cells alone carries very high risk.

  • What is apheresis, and does it hurt?

    It is machine-based blood component separation during a draw, taking about 2-4 hours. Mild tingling from the anticoagulant is common and manageable during the session.

  • Which cancer stages suit it?

    Typically in the post-primary-treatment setting to reduce recurrence risk, or as an adjunct where the physician judges it appropriate — not for every stage or cancer type.

  • Must I fly to Korea for every dose?

    Doses generally must be given at a licensed facility, so travel per scheduled cycle is required; plan the timetable and budget in advance.

Share this page

Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.

Back to categories

Related topics: Cell drug pipeline · Joints & immunity

See all in this category